Obstructive sleep apnea is a condition that disrupts rest, leading to symptoms such as daytime fatigue, brain fog and ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

Popular Eli Lilly weight-loss drug Zepbound can be covered by Medicare plans to treat sleep apnea after it received Food and ...

Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

Decreased blood flow of the optic nerve head (MA, MV, and MT measurements) was significantly correlated with increased OSA ...

Both Novo Nordisk and Eli Lilly are studying their weight loss drugs to treat fatty liver disease, chronic kidney disease, ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.